Año 2022 / Volumen 114 / Número 5
Revisión
Diagnostic accuracy of circulating microRNA in hepatitis B virus-related hepatocellular carcinoma: a meta-analysis based on Asian data

280-288

DOI: 10.17235/reed.2021.8139/2021

Wen-Ting Zhang, Antonio Gil-Gómez, Chang-Hai Liu, Shuai-Shuai Gao, Manuel Romero-Gómez,

Resumen
Background and aim: hepatitis B virus (HBV) is the main risk factor for hepatocellular carcinoma (HCC). We performed a meta-analysis based on Asian data to evaluate the diagnostic accuracy of circulating microRNA as a non-invasive biomarker in the diagnosis of HBV-related HCC. Methods: a comprehensive literature search (updated to May 12, 2021) in PubMed, Embase, Web of Science, Wanfang Database, and China National Knowledge Infrastructure (CNKI) was performed to identify eligible studies. The sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) for diagnosing HBV-related HCC were pooled in this meta-analysis. A subgroup analysis was performed to explore heterogeneity, and Deeks' funnel plot was used to assess publication bias. Results: a total of 19 articles including 32 studies were included in the current meta-analysis. The overall sensitivity, specificity, PLR, NLR, DOR and AUC were 0.83 (95 % CI: 0.79 to 0.87), 0.78 (95 % CI: 0.73 to 0.83), 3.9 (95 % CI: 3.0 to 4.9), 0.21 (95 % CI: 0.16 to 0.27), 18 (95 % CI: 12 to 27) and 0.88 (95 % CI: 0.85 to 0.91), respectively. Subgroup analysis shows that miRNA clusters with a large sample size showed better diagnostic accuracy. Although there is no publication bias, the research still has some limitations. Conclusions: circulating miRNAs could serve as a potential non-invasive biomarker in diagnosing HBV-related HCC in Asian populations.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Zhang L, Fan Y, Wang X, et al. Carbohydrate Sulfotransferase 4 Inhibits the Progression of Hepatitis B Virus-Related Hepatocellular Carcinoma and Is a Potential Prognostic Marker in Several Tumors. Frontiers in oncology 2020; 10: 554331.
2. Amaddeo G, Cao Q, Ladeiro Y, et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut 2015; 64: 820-9.
3. Tang A, Cruite I, Mitchell DG, et al. Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdominal radiology (New York) 2018; 43: 3-12.
4. Luo P, Wu S, Yu Y, et al. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathol Oncol Res 2020; 26: 599-603.
5. Pezzuto F, Buonaguro L, Buonaguro FM, et al. The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma. Int J Mol Sci 2018;19:1007.
6. Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nature reviews Gastroenterology & hepatology 2018; 15: 137-51.
7. Zhao XF, Li N, Lin DD, et al. Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis. BioMed research international 2020; 2020: 5353695.
8. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 2009; 6: e1000097.
9. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine 2011; 155: 529-36.
10. Swets JA. Measuring the accuracy of diagnostic systems. Science (New York, NY) 1988; 240: 1285-93.
11. Cao X, Yang Q, Yu Q. Increased Expression of miR-487b Is Associated With Poor Prognosis and Tumor Progression of HBV-Related Hepatocellular Carcinoma. Open forum infectious diseases 2020; 7: ofaa498.
12. Chen S, Chen H, Gao S, et al. Differential expression of plasma microRNA-125b in hepatitis B virus-related liver diseases and diagnostic potential for hepatitis B virus-induced hepatocellular carcinoma. Hepatol Res 2017; 47: 312-20.
13. Chen Y, Dong X, Yu D, et al. Serum miR-96 is a promising biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. International journal of clinical and experimental medicine 2015; 8: 18462-8.
14. Ghosh A, Ghosh A, Datta S, et al. Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma. International journal of cancer 2016; 138: 2732-44.
15. Li L, Guo Z, Wang J, et al. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Digestive diseases and sciences 2012; 57: 2910-6.
16. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer research 2010; 70: 9798-807.
17. Li X, Guo Y, Wang X, et al. Clinical significance of serum miR-487b in HBV-related hepatocellular carcinoma and its potential mechanism. Infectious diseases (London, England) 2021; 53: 546-54.
18. Lin L, Lu B, Yu J, et al. Serum miR-224 as a biomarker for detection of hepatocellular carcinoma at early stage. Clinics and research in hepatology and gastroenterology 2016; 40: 397-404.
19. Moradi N, Paryan M, Khansarinejad B, et al. Plasma Level of miR-5193 as a Novel Biomarker for Diagnosis of HBV-Related Hepatocellular Carcinoma. Hepat Mon 2019; 19: e84455.
20. Qi P, Cheng SQ, Wang H, et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PloS one 2011; 6: e28486.
21. Tan Y, Ge G, Pan T, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PloS one 2014; 9: e107986.
22. Xie Y, Yao Q, Butt AM, et al. Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer biology & therapy 2014; 15: 1248-55.
23. Xiong F, Ma H, Qu YC, et al. Profiles of serum miR-99a, let-7c and miR-125b in hepatitis B virus (HBV)-associated chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Int J Clin Exp Pathol 2016;9(7):7087-95.
24. Xu LJ, Wei B, Hui HX, et al. Association of serum microRNA-125b and HBV-related hepatocellular carcinoma in Chinese Han patients. Int J Clin Exp Med 2018;11(4):3699-703.
25. Yu F, Lu Z, Chen B, et al. microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma. Diagnostic pathology 2015; 10: 129.
26. Zhang W, Fu T, Guo Z, et al. Serum miR-375 Levels Are Closely Related to Disease Progression from HBV Infection to HBV-Related Hepatocellular Carcinoma. BioMed research international 2020; 2020: 5819385.
27. Zhao Q, Sun X, Liu C, et al. Expression of the microRNA-143/145 cluster is decreased in hepatitis B virus-associated hepatocellular carcinoma and may serve as a biomarker for tumorigenesis in patients with chronic hepatitis B. Oncology letters 2018; 15: 6115-22.
28. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. Journal of clinical oncology 2011; 29: 4781-8.
29. Zhu HT, Liu RB, Liang YY, et al. Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma. Liver international 2017; 37: 888-96.
30. Crotty M, Gnanamanickam ES, Cameron I, et al. Are people in residential care entitled to receive rehabilitation services following hip fracture? Views of the public from a citizens' jury. BMC Geriatr 2020; 20: 172-.
31. Peng C, Li Z, Xie Z, et al. The role of circulating microRNAs for the diagnosis of hepatitis B virus-associated hepatocellular carcinoma with low alpha-fetoprotein level: a systematic review and meta-analysis. BMC gastroenterology 2020; 20: 249.
32. Yin H, Sun Y, Wang X, et al. Progress on the relationship between miR-125 family and tumorigenesis. Experimental cell research 2015; 339: 252-60.
33. Gong J, Zhang JP, Li B, et al. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013; 32: 3071-9.
34. Li J, Fang L, Yu W, et al. MicroRNA-125b suppresses the migration and invasion of hepatocellular carcinoma cells by targeting transcriptional coactivator with PDZ-binding motif. Oncol Lett 2015; 9: 1971-5.
35. Hua S, Quan Y, Zhan M, et al. miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1. Cancer cell international 2019; 19: 203.
36. Zheng J, Zhou Z, Xu Z, et al. Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression. Molecular medicine reports 2015; 12: 1584-90.
37. Jin X, Cai C, Qiu Y. Diagnostic Value of Circulating microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Journal of Cancer 2019; 10: 4754-64.
Artículos relacionados

Editorial

Hemofilia y hepatología, un regreso al futuro

DOI: 10.17235/reed.2024.10105/2023

Carta

Reactivación del virus de la hepatitis B por ibrutinib

DOI: 10.17235/reed.2023.9587/2023

Imagen en Patología Digestiva

Hepatocarcinoma quístico gigante en ausencia de cirrosis

DOI: 10.17235/reed.2021.8313/2021

Carta

Biopsia en el carcinoma hepatocelular: solo en ocasiones

DOI: 10.17235/reed.2020.6935/2020

Carta

Diagnóstico de hepatocarcinoma. Una reflexión necesaria

DOI: 10.17235/reed.2020.6845/2019

Carta

Rabdomiolisis en paciente en tratamiento con sorafenib

DOI: 10.17235/reed.2020.6440/2019

Caso Clínico

Hepatocarcinoma sobre hígado ectópico peritoneal

DOI: 10.17235/reed.2019.6408/2019

Imagen en Patología Digestiva

Debut de cirrosis hepática poco habitual

Instrucciones para citar
Zhang W, Gil-Gómez A, Liu C, Gao S, Romero-Gómez M. Diagnostic accuracy of circulating microRNA in hepatitis B virus-related hepatocellular carcinoma: a meta-analysis based on Asian data. 8139/2021


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1623 veces.
Este artículo ha sido descargado 101 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 05/06/2021

Aceptado: 26/07/2021

Prepublicado: 23/08/2021

Publicado: 06/05/2022

Tiempo de revisión del artículo: 46 días

Tiempo de prepublicación: 79 días

Tiempo de edición del artículo: 335 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas